Wasn't the data based on only 1 patient? Patient 1 data seemed to be very good, but patient 2 data didn't seem good to me, unless I'm missing something. I think HTBX has potential, but you have to see the full study data to determine safety and efficacy. I feel like this data was cherry-picked.
Leo pumping the stock again based on government initiatives. I mean, come on Leo...you can do A LOT better than that. This guy is a fantastic...not just a fool...but a fantastic fool. He is a pumper...plain and simple. How can you not see it with this press release? It's a joke, by an OTC listed stock where the founders own a lot of shares. And, recall, how Leo and Menon finally capitulated and granted stock to the other CTIX founder, who they pushed aside initially. These guys are so shady.
Leo cherry-picks one Kevetrin patient who did so well that the patient had to leave the trial...LOL! CTIX buys Polymedix for $5 million and says it's just as good, if not better, than Cubist's billion dollar drug. I guess the Polymedix shareholders thought the same thing before it went bankrupt. And, clearly Merck was laughing when it did its research on the antibiotic market and bought Cubist instead of buying CTIX (and also getting this amazing Kevetrin and Prurisol) for 15x less. Oh by the way, Novartis just got approval for their highly effective anti-psoriasis drug the other day.
Be very careful owning CTIX...look for dilution soon. These hospital systems are not charity organizations. They are not going to run advanced trials for free. There are no partnerships coming.
Take your emotions out of the stock and just follow the stock promotion very closely.